Pasi Janne
机构: Dana Farber Cancer Institute
每年引用次数
引用次数
引用: 134,728
H-指数: 163
I10-指数 : 547
出版物: 1,257
High Risk of Brain Metastases in Surgically Staged IIIA Non–Small-Cell Lung Cancer Patients Treated With Surgery, Chemotherapy, and Radiation
Harvey J. Mamon , Beow Yong Yeap , Pasi A. Jänne , Jason Reblando
Journal of Clinical Oncology 23 ( 7) 1530 -1537
135
2005
Phase I to II Study of Pleurectomy/Decortication and Intraoperative Intracavitary Hyperthermic Cisplatin Lavage for Mesothelioma
William G. Richards , Lambros Zellos , Raphael Bueno , Michael T. Jaklitsch
Journal of Clinical Oncology 24 ( 10) 1561 -1567
152
2006
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
David A. Eberhard , Bruce E. Johnson , Lukas C. Amler , Audrey D. Goddard
Journal of Clinical Oncology 23 ( 25) 5900 -5909
1,306
2005
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Pasi A. Jänne , Nathanael Gray , Jeff Settleman
Nature Reviews Drug Discovery 8 ( 9) 709 -723
262
2009
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.
Natalie I. Vokes , David Liu , Biagio Ricciuti , Elizabeth Jimenez-Aguilar
JCO precision oncology 3 ( 3) 1 -12
23
2019
Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis.
Jacob M. Sands , Pasi A. Jänne , Geoffrey R. Oxnard , Yi Lee
JCO precision oncology 4 ( 4) 1098 -1108
2020
ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas
Lynette M. Sholl , Heather Sun , Mohit Butaney , Chengsheng Zhang
The American Journal of Surgical Pathology 37 ( 9) 1441 -1449
125
2013
Outcomes by EGFR, KRAS, and ALK Genotype After Combined Modality Therapy for Locally Advanced Non–Small-Cell Lung Cancer
Raymond H. Mak , Gretchen Hermann , Hugo J. Aerts , Elizabeth H. Baldini
JCO Precision Oncology 2 ( 2) 1 -18
1
2018
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
David M. Jackman , Hedy L. Kindler , Beow Y. Yeap , Panos Fidias
Cancer 113 ( 4) 808 -814
93
2008
Response to Treatment and Survival of Patients with Non-Small Cell Lung Cancer Undergoing Somatic EGFR Mutation Testing
Lecia V. Sequist , Victoria A. Joshi , Pasi A. Jänne , Alona Muzikansky
Oncologist 12 ( 1) 90 -98
140
2007
Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors.
Dries J. H. De Clercq , David E. Heppner , Ciric To , Jaebong Jang
ACS Medicinal Chemistry Letters 10 ( 11) 1549 -1553
9
2019
LKB1 modulates lung cancer differentiation and metastasis
Hongbin Ji , Matthew R. Ramsey , D. Neil Hayes , Cheng Fan
Nature 448 ( 7155) 807 -810
1,107
2007
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma
Marie-Julie Nokin , Elodie Darbo , Camille Travert , Benjamin Drogat
JCI insight 5 ( 15) 1 -13
12
2020
Multiparametric profiling of non–small-cell lung cancers reveals distinct immunophenotypes
Patrick H Lizotte , Elena V Ivanova , Mark M Awad , Robert E Jones
JCI insight 1 ( 14)
121
2016
Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Thomas E. Stinchcombe , Pasi A. Jänne , Xiaofei Wang , Erin M. Bertino
JAMA Oncology 5 ( 10) 1448 -1455
26
2019
Discovery of selective irreversible inhibitors for EGFR-T790M
Wenjun Zhou , Dalia Ercan , Pasi A. Jänne , Nathanael S. Gray
Bioorganic & Medicinal Chemistry Letters 21 ( 2) 638 -643
85
2011
s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis
Jin Li , Ross Berbeco , Robert J. Distel , Pasi A. Jänne
Nucleic Acids Research 35 ( 12)
25
2007
New Targetable Oncogenes in Non–Small-Cell Lung Cancer
Geoffrey R. Oxnard , Adam Binder , Pasi A. Jänne
Journal of Clinical Oncology 31 ( 8) 1097 -1104
359
2013
KRAS Wild-Type Lung Cancer: A Moving Target in an Era of Genotype Migration
Geoffrey R. Oxnard , Pasi A. Jänne
Journal of Clinical Oncology 30 ( 27) 3322 -3324
11
2012
Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
Frances A Shepherd , Caroline Domerg , Pierre Hainaut , Pasi A Jänne
Journal of Clinical Oncology 31 ( 17) 2173 -2181
188
2013